High-risk groups requiring liver cancer risk screening
Regular risk assessments for liver cancer are required if any of the following risk factors occur.
History of hepatitis B/C virus infection
Metabolic dysfunction-associated steatohepatitis (MASH)
Liver cirrhosis due to other causes
Male above 40 years
Excessive alcohol drinking
Family history of liver cancer
Risk Assessment Criteria of Liver Fibrosis
Scoring and Application
My FibroScan Score
National "12th Five-Year Plan" and "13th Five-Year Plan" Major Science and Technology Projects Research
Compound Biejia Ruangan Tablets combined with antiviral drugs can significantly reduce the incidence of liver cancer
This achievement was published in the top hepatology journal Journal of Hepatology (IF 30.083). It is the first clinical study presenting high-level evidence in an international top-tier academic journal demonstrating that traditional Chinese medicine can reverse liver fibrosis and reduce liver cancer incidence. This work overcomes the longstanding lack of internationally recognized clinical evidence, especially regarding the most critical aspects of clinical efficacy and safety. It significantly elevates the status of traditional Chinese medicine in the global academic community and represents a groundbreaking milestone not only for hepatology but for the field of traditional Chinese medicine.
Focused on comprehensive chronic liver disease management, providing compassionate liver disease insurance
Huiganbao: China’s first insurance exclusively for chronic liver disease patients
01
Regular liver function monitoring allowance
02
Priority medical resource access service
03
Cross-provincial surgery allowance coverage
04
Liver cancer treatment insurance compensation
05
Internet hospital management allowance
